HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma

References

• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296.
   PubMed Web of Science ®Google Scholar
• Benedet JL, Bender H, Jones H, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70(2):209–262.
   PubMed Web of Science ®Google Scholar
• Hall M, Bertelli G, Li L, et al. Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. Int J Gynecol Cancer. 2020;30(2):213–218.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Pignata S, Ledermann JA. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol. 2018;29(6):1366–1376.
   PubMed Web of Science ®Google Scholar
• Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 2011;12(12):1169–1174.
   PubMed Web of Science ®Google Scholar
• Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers. Int J Gynecol Cancer. 2016;26(1):43–51.
   PubMed Web of Science ®Google Scholar
• Bast RC, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15(S3):274–281.
   PubMed Web of Science ®Google Scholar
• Chi DS, Venkatraman ES, Masson V, et al. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol. 2000;77(2):227–231.
   PubMed Web of Science ®Google Scholar
• Kang S, Kim TJ, Nam BH, et al. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol. 2010;101(1):13–17.
   PubMed Web of Science ®Google Scholar
• Barlow TS, Przybylski M, Schilder JM, et al. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer. 2006;16(2):496–500.
   PubMed Web of Science ®Google Scholar
• Mury D, Woelber L, Jung S, et al. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer. J Cancer Res Clin Oncol. 2011;137(7):1131–1137.
   PubMed Web of Science ®Google Scholar
• Muinao T, Deka Boruah HP, Pal M. Diagnostic and prognostic biomarkers in ovarian cancer and the potential roles of cancer stem cells – an updated review. Exp Cell Res. 2018;362(1):1.
   PubMed Web of Science ®Google Scholar
• Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45(2):350–357.
   PubMed Web of Science ®Google Scholar
• Ferraro S, Panteghini M. Making new biomarkers a reality: the case of serum human epididymis protein 4. Clin Chem Lab Med. 2019;57(9):1284–1294.
   PubMed Web of Science ®Google Scholar
• Trudel D, Têtu B, Grégoire J, et al. Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol. 2012;127(3):511–515.
   PubMed Web of Science ®Google Scholar
• Yuan C, Li R, Yan S, et al. Prognostic value of HE4 in patients with ovarian cancer. Clin Chem Lab Med. 2018;56(7):1026–1034.
   PubMed Web of Science ®Google Scholar
• Kalapotharakos G, Asciutto C, Henic E, et al. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res. 2012;5(1):20–29.
   PubMed Web of Science ®Google Scholar
• Feng LY, Bin Liao S, Li L. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study. J Ovarian Res. 2020;13(1):17.
   PubMed Web of Science ®Google Scholar
• Ferraro S, Robbiano C, Tosca N, et al. Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up. Clin Biochem. 2018;60:84–90.
   PubMed Web of Science ®Google Scholar
• Colombo N, Sessa C, Du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019;29(4):728–760.
   Web of Science ®Google Scholar
• Kappelmayer J, Antal-Szalmás P, Nagy B. Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders. Clin Chim Acta. 2015;438:35–42.
   PubMed Web of Science ®Google Scholar
• John G, Rustin S, Vergote I, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–423.
   PubMed Web of Science ®Google Scholar
• Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–207.
   PubMed Web of Science ®Google Scholar
• Isoviita VM, Salminen L, Azar J, et al. Open source infrastructure for health care data integration and machine learning analyses. J Clin Oncol Clin Cancer Inform. 2019;3:1–16.
   PubMedGoogle Scholar
• Diamandis E, Fritsche H, Lilja H, et al. Tumor markers. Physiology, pathobiology, technology, and clinical applications. 1st ed. Washington (DC): AACC Press; 2003.
   Google Scholar
• Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol. 2005;16(1):47–50.
   PubMed Web of Science ®Google Scholar
• Prat A, Parera M, Peralta S, et al. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol. 2008;19(2):327–331.
   PubMed Web of Science ®Google Scholar
• Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101(23):1642–1649.
   PubMed Web of Science ®Google Scholar
• Angioli R, Plotti F, Capriglione S, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2013;128(3):579–583.
   PubMed Web of Science ®Google Scholar
• Braicu EI, Fotopoulou C, Van Gorp T, et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2013;128(2):245–251.
   PubMed Web of Science ®Google Scholar
• Vallius T, Hynninen J, Auranen A, et al. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer. Tumor Biol. 2017;39.
   Google Scholar
• Van Altena AM, Kolwijck E, Spanjer MJB, et al. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. Gynecol Oncol. 2010;119(2):265–269.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang Y, Wang F, et al. Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer. J Ovarian Res. 2013;6(1):31–38.
   PubMed Web of Science ®Google Scholar
• Kang S, Seo SS, Park SY. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer. J Surg Oncol. 2009;100(3):244–247.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Kristeleit RS. Optimal treatment for relapsing ovarian cancer. Ann Oncol. 2010;21:vii218–vii222.
   PubMed Web of Science ®Google Scholar